Vertex Pharmaceuticals Incorporated (FRA:VX1)

Germany · Delayed Price · Currency is EUR

404.85

-8.25 (-2.00%)

At close: Jan 9, 2026

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2011 - 2020
Trikafta / Kaftrio Revenue	10.46B	10.24B	Log In	Log In	Log In	Upgrade
Symdeko / Symkevi Revenue	-	-	Log In	Log In	Log In	Upgrade
Orkambi Revenue	-	-	Log In	Log In	Log In	Upgrade
Kalydeco Revenue	-	-	Log In	Log In	Log In	Upgrade
Casgevy Revenue	69.50M	10.00M	Log In	Log In	Log In	Upgrade
Other Product Revenue	773.90M	781.50M	Log In	Log In	Log In	Upgrade
Net Product Revenue	11.69B	11.02B	Log In	Log In	Log In	Upgrade
Other Collaborative and Royalty Revenue	-	-	Log In	Log In	Log In	Upgrade
Revenue (Total)	11.69B	11.02B	Log In	Log In	Log In	Upgrade

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2011 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2011 - 2020
Other Collaborative and Royalty Revenue	-	-	Log In	Log In	Log In	Upgrade
United States Product Revenue	7.29B	6.68B	Log In	Log In	Log In	Upgrade
Outside of United States Product Revenue	4.40B	4.34B	Log In	Log In	Log In	Upgrade
Revenue (Total)	11.69B	11.02B	Log In	Log In	Log In	Upgrade

Updated Sep 30, 2025. Data Source: Fiscal.ai.